Pregunta 1
Pregunta
Varices appeared to be the source of bleeding in 50 to 90 percent of patients with cirrhosis
Pregunta 2
Pregunta
In patients with cirrhosis, any upper gastrointestinal bleeding associated with hemodynamic changes should be considered to be variceal in origin until proven otherwise.
Pregunta 3
Pregunta
Early rebleeding – Bleeding that occurs >120 hours but <6 weeks from time zero,
Pregunta 4
Pregunta
Only 50 percent of patients with variceal hemorrhage stop bleeding spontaneously
Pregunta 5
Pregunta
Cuando la presión portal pasa de 10 mmHg se incrementa potencialmente el desarrollo de colaterales.
Pregunta 6
Pregunta
Se define como hipertensión portal un gradiente de presión venosa hepática mayor a 5 mmHg, y el valor de 12 mmHg es un factor de riesgo para predecir hemorragia variceal.
Pregunta 7
Pregunta
a hepatic venous pressure gradient >20 mmHg is associated with a greater risk of continued or recurrent bleeding
Pregunta 8
Pregunta
50 percent of all early rebleeding episodes occur within the first 10 days
Pregunta 9
Pregunta
The risk of bleeding and of death in patients who survive six weeks is similar to that in patients with cirrhosis of equivalent severity who have never bled
Pregunta 10
Pregunta
Acute bleeding from varices is associated with approximately 15 to 20 percent 30-day mortality
Pregunta 11
Pregunta
Platelet counts often drop within the first 48 hours after a bleed and may necessitate platelet transfusions if values below 50,000/mm3
Pregunta 12
Pregunta
Bacterial infections are present in up to 20 percent of patients with cirrhosis who are hospitalized with gastrointestinal bleeding
Pregunta 13
Pregunta
effectiveness of prophylactic antibiotics in patients with cirrhosis hospitalized for bleeding suggest an overall reduction in infectious complications and decreased mortality
Pregunta 14
Pregunta
A systematic review that included eight placebo-controlled trials with a total of 864 patients found the antibiotics were associated with a significant reduction in mortality (RR 0.75, 95% CI 0.55 to 0.95) and bacterial infections (RR 0.40, 95% CI 0.32 to 0.51) including bacteremia, pneumonia, spontaneous bacterial peritonitis, and urinary tract infections
Pregunta 15
Pregunta
patients with cirrhosis who present with upper GI bleeding (from varices or other causes) should be given prophylactic antibiotics, preferably before endoscopy
Pregunta 16
Pregunta
fOR PREVENTION OF INFECTIONS, intravenous ceftriaxone (1 g/day for seven days), which was superior to norfloxacin in a randomized controlled trial [
Pregunta 17
Pregunta
Short-term (maximum seven days) antibiotic prophylaxis should be instituted in any patient with cirrhosis and GI hemorrhage.
Pregunta 18
Pregunta
Among patients with cirrhosis, varices form at a rate of 5 to 15 percent per year, and one-third of patients with varices will develop variceal hemorrhage
Pregunta 19
Pregunta
Treatment with endoscopic variceal ligation decreases the risk of rebleeding to approximately 30 percent, and the risk of death to approximately 25 percent.
Pregunta 20
Pregunta
Endoscopic sclerotherapy is associated with a decrease in the risk of rebleeding to 40 to 50 percent, and a decrease in the risk of death to 30 to 60 percent
Pregunta 21
Pregunta
Pharmacologic therapy should not be delayed pending confirmation that the source of bleeding is indeed from varices
Pregunta 22
Pregunta
pharmacologic therapy typically consists of an octreotide bolus (50 mcg intravenous [IV]) followed by a continuous infusion (50 mcg IV per hour).
Pregunta 23
Pregunta
Terlipressin is administered at an initial dose of 2 mg IV every four hours and can be titrated down to 1 mg IV every four hours once hemorrhage is controlled
Pregunta 24
Pregunta
Pharmacologic therapy is typically continued for three to five days following cessation of bleeding
Pregunta 25
Pregunta
The goal should be to perform an upper endoscopy after fluid resuscitation and within 12 hours of presentation
Pregunta 26
Pregunta
If the bleeding cannot be controlled endoscopically, treatment options include transjugular intrahepatic portosystemic shunt (TIPS) placement or surgical shunting
Pregunta 27
Pregunta
terlipressin is the only agent individually shown to reduce mortality
Pregunta 28
Pregunta
— Vasopressin can achieve initial hemostasis in 60 to 80 percent of patients, but has only marginal effects on early rebleeding episodes and does not improve survival from active variceal hemorrhage [12].
Pregunta 29
Pregunta
terlipressin is released in a slow and sustained manner, permitting its administration via intermittent injections.
Pregunta 30
Pregunta
terlipressin has been associated with hyponatremia,
Pregunta 31
Pregunta
A study comparing the acute hemodynamic effects of terlipressin to octreotide in stable patients with cirrhosis found a sustained effect of terlipressin on portal pressure and blood flow compared with only a transient effect from octreotide
Pregunta 32
Pregunta
Somatostatin inhibits the release of vasodilator hormones such as glucagon [20], indirectly causing splanchnic vasoconstriction and decreased portal inflow.
Pregunta 33
Pregunta
the most consistently delocteotride observed is the decrease in collateral flow (azygos flow)
Pregunta 34
Pregunta
While somatostatin and octreotide help achieve hemostasis and prevent rebleeding, neither has a clearly established benefit on mortality [
Pregunta 35
Pregunta
A systematic review found that combination therapy with somatostatin or octreotide and endoscopic variceal ligation improved the five-day success rate compared with endoscopic variceal ligation alone